Company: PTHS
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001753926-25-000503
Chunk: 1613

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 8
Chunk 1613
---
000  
    $7.50  
     4.38 

    F-24 

A
summary of the status of the Company’s nonvested warrants as of December 31, 2024, and changes during the year ended December
31, 2024, is presented below:

 Schedule
of  nonvested warrants

    Non-vested
    Warrants
     
    Warrants

    Weighted-
    Average
    Exercise
    Price

    Non-vested at December 31,
    2023

    —

    $
    —

    Granted

    55,000

    $
    7.50

    Vested

    (55,000
    )
     
    $
    7.50

    Forfeited

    —

    $
    —

    Non-vested at
    December 31, 2024

    —

    $
    —

The
total number of warrants granted during the years ended December 31, 2024 and 2023 was 55,000 and 0, respectively.
The exercise price for these warrants was $7.50 per share and there was an intrinsic value of $0.

The
Company recognized stock-based compensation expense related to warrant vesting amortization of $0 and $0 for the years ended December
31, 2024 and 2023, respectively.

On
February 21, 2024, the Company issued warrants to purchase up to 55,000 shares of Common Stock to the representative of the
underwriters of the IPO (the “Representative”). These warrants have an exercise price of $7.50, have a cashless exercise
provision, are exercisable 180 days following the commencement of sales of the shares of Common Stock of the IPO and have an expiration
date of February 21, 2029. No expense was recognized to the warrants issued to such warrants from the IPO as these warrants constituted
offering costs of the IPO.

RSUs

A
summary of the status of the Company’s nonvested RSUs as of December 31, 2024, and changes during the year ended December
31, 2024, is presented below:

 Schedule
of nonvested RSUs

    Non-vested RSUs 
    RSUs  
    Weighted- Average Exercise Price 

    Non-vested at December 31, 2023